Prudentia Sciences

About Prudentia Sciences

Prudentia Sciences aims to build the drug asset marketplace of the future by empowering biopharma to accelerate drug pipelines, maximize ROI, and achieve clinical and commercial success for greater patient impact. It also enables investors and biopharma to position and showcase asset value during portfolio strategy and dealmaking, while equipping investors with data-driven insights for optimal capital allocation in drug asset transactions.

Products & Services

Prudentia Platform:An AI-powered platform for asset diligence and valuation to de-risk investment in drug development. Features include real-time data-driven simulation, scenario planning, AI-guided product profiles, asset valuations, integrative analytics for due diligence, portfolio optimization, and expert in-the-loop deal analysis.

Integrative Analytics for Due Diligence:Rapid AI-powered synthesis of data room into an asset assessment framework and product profile for comparison with public and proprietary data to optimize development plans and determine risks and value drivers.

Portfolio Optimization:AI-guided product profiles and asset valuations to support portfolio strategy and decision-making.

Value Simulation:Real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms and increase deal throughput.

Expert In-the-loop:Multi-disciplinary expert analysis and modeling with real-time analytics for AI-accelerated insights across asset value and risk dimensions.

Specialties

AI-powered Asset Diligence and Valuation Drug Development Portfolio Strategy Data-driven Insights Due Diligence Analytics Real-time Simulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2026-01-07 FD: 2026-01-07	5 investors
2	RT: Seed T: - FT: Seed	A: 7000000 MR: - FA: $7 million FAN: 7000000	D: 2025-01-09 FD: 2025-01-09	3 investors

Series A Latest

2026-01-07

$20.0M

5 investors (Pro only)

Seed 2025-01-09

$7.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sadiqa Mahmood

CEO & Founder

LinkedIn (Pro only)

J

John Reynders, PhD

Chief Technology Officer

LinkedIn (Pro only)

D

Duc Do, PhD

Senior Data Scientist

LinkedIn (Pro only)

B

Benjamin Fleming

Senior Software Engineer

A

Alex Dreo

Senior Data Engineer

W

Wasim Malik, PhD

Founding Board Member, Managing Partner at Iaso Ventures

View 6 more team members with Pro

Unlock Full Team Directory

Recent News